Medicinal Products

Imbruvica

Name Imbruvica
Active Substance ibrutinib
Prescription na recept
Type of prescription ograničeni recept
Distribution u ljekarni
ATC Code L01XE27
Medicinal product marketed in the Croatia Da

Note

The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica

The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima o potrebi za probirom bolesnika na virus hepatitisa B prije početka liječenja ibrutinibom (Imbruvica) zbog rizika od reaktivacije hepatitisa B 27.07.2017 Janssen-Cilag International N.V. i Johnson & Johnson S.E. d.o.o.
Back